DYN Q2 2024 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$72M

Net Income

-$65M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$56M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$826M

Total Liabilities

$51M

Stockholders' Equity

$775M

Cash & Equivalents

$608M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$72M	-$67M	-7.8%
Net Income	-$65M	-$65M	-0.3%